Alembic Pharmaceuticals is currently trading at Rs. 526.75, up by 13.90 points or 2.71% from its previous closing of Rs. 512.10 on the BSE.
The scrip opened at Rs. 517.95 and has touched a high and low of Rs. 526.00 and Rs. 515.00 respectively. So far 445 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 664.00 on 27-Sep-2018 and a 52 week low of Rs. 435.10 on 21-Jun-2019.
Last one week high and low of the scrip stood at Rs. 529.15 and Rs. 507.50 respectively. The current market cap of the company is Rs. 9859.38 crore.
The promoters holding in the company stood at 72.97%, while Institutions and Non-Institutions held 14.97% and 12.06% respectively.
Alembic Pharmaceuticals has received tentative approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) Dapagliflozin Tablets, 5 mg and 10 mg. The approved ANDA is therapeutically equivalent to the reference listed drug (RLD) Farxiga Tablets, 5 mg and 10 mg, of AstraZeneca AB (AstraZeneca). Dapagliflozin Tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
Dapagliflozin Tablets have an estimated market size of $1.7 billion for twelve months ending December 2018 according to IQVIA.
Alembic now has a total of 99 ANDA approvals (88 final approvals and 11 tentative approvals) from USFDA.
Alembic Pharmaceuticals, a vertically integrated research and development pharmaceutical company, has been at the forefront of Healthcare since 1907.
Company Name | CMP |
---|---|
Sun Pharma Inds. | 1525.00 |
Dr. Reddys Lab | 5942.65 |
Cipla | 1345.35 |
Zydus Lifesciences | 925.95 |
Lupin | 1547.05 |
View more.. |